Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jan 18;15(1):22.
doi: 10.1186/s12974-017-1043-y.

Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures

Affiliations
Comparative Study

Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures

S Jarius et al. J Neuroinflammation. .

Abstract

Background: Baló's concentric sclerosis (BCS) is a rare inflammatory demyelinating disorder of the central nervous system characterised by concentric layers of demyelination. It is unclear whether BCS is a variant of multiple sclerosis (MS) or a disease entity in its own right.

Objective: To compare the cerebrospinal fluid (CSF) features of BCS to those of MS.

Methods: Retrospective analysis of the CSF profile of all patients with BCS reported in the medical literature between 1980 and 2017.

Results: In total, the results of 146 lumbar punctures (LP) in 132 patients were analysed. The most striking finding was a lack of CSF-restricted oligoclonal bands (OCB) in 66% (56/85) of all LP in the total BCS group, in 74% (14/19) in the subgroup of patients with both MRI and histological evidence for BCS, and in 82% (18/22) in the subgroup of patients with highest radiological confidence (high MRI quality, ≥ 3 layers of demyelination). OCB disappeared in 1/2 initially OCB-positive patients. These findings are in stark contrast to MS, in which OCB are present in ≥ 95% of patients and are thought to remain stably detectable over the entire course of disease (p < 0.000001). OCB frequency was low both in 'historic' patients (1980-2009; 37%) and in more recent patients (2010-2017; 31%). OCB-positive and OCB-negative patients did not differ significantly with regard to age, sex, disease duration, number of Baló-like lesions on MRI, number of relapses, treatment or final outcome. In accordance with the high rate of OCB negativity, Link's IgG index was negative in 63% of all tested samples (p < 0.000001 vs. MS). CSF pleocytosis was present in 28% (27/96; p < 0.000001 vs. MS) and elevated CSF total protein levels in 41% (31/76) of samples.

Conclusion: OCB and IgG index frequencies in BCS are much more similar to those reported in neuromyelitis optica or myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis than to those in MS. Our findings suggest that in most cases BCS-like lesions denote the presence of a disease entity immunologically distinct from MS. In addition, we provide data on the demographics, clinical course and radiological features of BCS based on the largest cohort analysed to date.

Keywords: Baló; Baló’s concentric sclerosis (BCS); Cerebrospinal fluid (CSF); Diagnosis; Histopathology; Immunology/immunopathology; Intrathecal IgG synthesis; Link’s IgG index; Lumbar puncture; Magnetic resonance imaging; Multiple sclerosis (MS); Oligoclonal bands (OCB); Pattern III MS; Pleocytosis; Review of the literature.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

B.W. has received research grants, speaking fees and travel grants from Merck Serono, Biogen, Teva, Novartis, Sanofi Genzyme, Bayer Healthcare, Biotest and the Dietmar Hopp Foundation. F.P. has received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation and the US National Multiple Sclerosis Society; has received travel funding and/or speaker honoraria from Bayer, Novartis, Biogen Idec, Teva, SanofiAventis/Genzyme and Merck Serono; and has consulted for Sanofi Genzyme, Biogen Idec and MedImmune; none of this is related to the present paper. The other authors report no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Frequency of CSF-restricted OCB in MS (N = 276) [17], BCS (present study; N = 146), NMOSD (N = 144) [4] and MOG-EM (N = 45) [11]. AQP4+ aquaporin-4-IgG-positive, AQP4− aquaporin-4-IgG-negative, BCS Baló’s concentric sclerosis, HQ-MRI high-quality MRI subgroup (see the ‘Results’ section for details), MOG-EM myelin oligodendrocyte glycoprotein antibody-positive encephalomyelitis, MS multiple sclerosis, NMOSD neuromyelitis optica spectrum disorders

Similar articles

Cited by

References

    1. Hardy TA, Miller DH. Balo’s concentric sclerosis. Lancet Neurol. 2014;13:740–746. doi: 10.1016/S1474-4422(14)70052-3. - DOI - PubMed
    1. Baló J. Encephalitis periaxialis concentrica. Arch NeurPsych. 1928;19:242–246. doi: 10.1001/archneurpsyc.1928.02210080044002. - DOI
    1. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82–90. doi: 10.1016/j.jns.2011.03.038. - DOI - PubMed
    1. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. doi: 10.1186/1742-2094-9-14. - DOI - PMC - PubMed
    1. Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, Wildemann B. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264:453–466. doi: 10.1007/s00415-016-8360-4. - DOI - PubMed

Publication types

MeSH terms